TABLE 5.
Re‐evaluation of morae after BT injection in non‐responders
| Morae | ||||||
|---|---|---|---|---|---|---|
| Case ID | BT inj. | Normal/abnormal | Normal/mild/severe | (S) in GRBAS | VHI | VAS |
| 01‐01 (BT group) | Baseline | 1/24 | 1/0/24 | 3 | 95 | 100 |
| Initial inj. | 1/24 | 1/0/24 | 3 | 79 | 73 | |
| 1st re‐inj. | 1/24 | 1/6/18 | 1 | 62 | 50 | |
| 2nd re‐inj. | 1/24 | 1/16/8 | 1 | 78 | 75 | |
| 02‐03 (Placebo group) | Baseline | 1/24 | 1/0/24 | 2 | 53 | 64 |
| Initial inj. | 1/24 | 1/0/24 | 3 | 61 | 66 | |
| 1st re‐inj. | 1/24 | 1/5/19 | 1 | 40 | 43 | |
| 07‐02 (BT group) | Baseline | 3/22 | 1/2/22 | 2 | 82 | 47 |
| Initial inj. | 1/24 | 1/9/15 | 2 | 67 | 43 | |
| 1st re‐inj. | 2/23 | 2/14/9 | 2 | 63 | 39 | |
| 2nd re‐inj. | 1/24 | 1/19/5 | 2 | 65 | 41 | |
Abbreviations: BT, botulinum toxin; inj., injection.